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Abstract 
Biosensors are nowadays ubiquitous in biomedical diagnosis as well as a wide range of other 
areas such as point-of-care monitoring of treatment and disease progression, environmental 
monitoring, food control, drug discovery, forensics and biomedical research. A wide range of 
techniques can be used for the development of biosensors. Their coupling with high affinity 
biomolecules allows the sensitive and selective detection of a range of analytes. 
We here give a general introduction to biosensors and biosensing technologies, including a 
brief historical overview, introducing key developments in the field and illustrate the breadth 
of biomolecular sensing strategies and the expansion of nanotechnological approaches that 
are now available. 
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Introduction 
A biosensor is a device that measures biological or chemical reactions by generating signals 
proportional to the concentration of an analyte in the reaction. Biosensors are employed in 
applications such as disease monitoring, drug discovery, for the detection of pollutants, 
disease causing microorganisms and markers that are indicators of a disease in bodily fluids 
(blood, urine, saliva, sweat). A typical biosensor is represented in Figure 1 – it consists of the 
following components: 
 Analyte 
It is a substance of interest that needs detection. For instance glucose is an ‘analyte’ in a 
biosensor designed to detect glucose. 
 Bioreceptor 
A molecule that specifically recognises the analyte is known as bioreceptor. Enzymes, cells, 
aptamers, DNA and antibodies are some examples of bioreceptors. The process of generation 
of a signal (in the form of light, heat, pH, charge or mass change, etc.) upon interaction of the 
bioreceptor with the analyte is termed as bio-recognition. 
 Transducer  
The transducer is an element that converts one form of energy into another. In a biosensor the 
role of the transducer is to convert the bio-recognition event into a measurable signal. This 
process of conversion of the energy is known as signalisation. Most transducers produce 
either optical or electrical signals that are usually proportional to the amount of 
analyte/bioreceptor interactions.  
 Electronics 
This is the part of a biosensor that processes the transduced signal and prepares it for being 
displayed. It consists of complex electronic circuitry that performs signal conditioning such 
as amplification and conversion of signals from analog to the digital form. The processed 
signals are then quantified by the display unit of the biosensor. 
 Display 
The display consists of a user interpretation system such as liquid crystal display of a 
computer or a direct printer that generates numbers or curves understandable by the user. 
This part often consists of a combination of hardware and software that generates results of 
the biosensor in a user friendly manner. The output signal on the display can be numeric, 
graphic, tabular or an image, depending on the requirements of the end user. 
 
 
Figure 1 Schematic representation of a biosensor.  
 
Historical Background  
The history of biosensors dates back to as early as 1906 when M. Cremer demonstrated that 
the concentration of an acid in a liquid is proportional to the electric potential that arises 
between parts of the fluid located on opposite sides of a glass membrane [1]. However, it was 
only in 1909 that the concept of pH (hydrogen ion concentration) was introduced by Søren 
Peder Lauritz Sørensen and an electrode for pH measurements was realised in the year 1922 
by W.S. Hughes [2]. In between 1909-22, Griffin and Nelson first demonstrated 
immobilisation of the enzyme invertase on aluminium hydroxide and charcoal [3,4]. The first 
‘true’ biosensor was developed by Leland C. Clark Jnr in 1956 for oxygen detection. He is 
known as the ‘father of biosensors’ and his invention of the oxygen electrode bears his name: 
‘Clark electrode’. The demonstration of an amperometric enzyme electrode for the detection 
of glucose by Leland Clark in 1962 was followed by the discovery of the first potentiometric 
biosensor to detect urea in 1969 by Guilbault and Montalvo [6]. Eventually in 1975 the first 
commercial biosensor was developed by Yellow Spring Instruments (YSI). Table 1 shows the 
historical overview of biosensors in the period 1970-1992. Ever since the development of the 
i-STAT sensor, remarkable progress has been achieved in the field of biosensors. The field is 
now a multidisciplinary area of research that bridges the principles of basic sciences (physics, 
chemistry and biology) with fundamentals of micro/nanotechnology, electronics and 
applicatory medicine. The database ‘Web of Science’ has indexed over 84,000 reports on the 
topic ‘biosensors’ from 2005-2015.  
 
Table 1. Important cornerstones in the development of biosensors during the period 1970-
1992. 
1970 Discovery of ion-sensitive field effect transistor (ISFET) by Bergveld [7] 
1975 Fibre optic biosensor for carbon dioxide and oxygen detection by Lubbers and 
Opitz [8] 
1975 First commercial biosensor for glucose detection by YSI [9] 
1975 First microbe based immunosensor by Suzuki et al. [ 10] 
1982 Fibre optic biosensor for glucose detection by Schultz [11] 
1983 Surface plasmon resonance (SPR) immunosensor by Liedberg et al. [12] 
1984 First mediated amperometric biosensor: ferrocene used with glucose oxidase for 
glucose detection [13] 
1990 SPR based biosensor by Pharmacia BIACore [8] 
1992 Hand-held blood biosensor by i-STAT [8] 
 
Characteristics of a biosensor  
There are certain static and dynamic attributes that every biosensor possesses. The 
optimisation of these properties is reflected on the performance of the biosensor.   
Selectivity 
Selectivity is perhaps the most important feature of a biosensor. Selectivity is the ability of a 
bioreceptor to detect a specific analyte in a sample containing other admixtures and 
contaminants. The best example of selectivity is depicted by the interaction of an antigen 
with the antibody. Classically, antibodies act as bioreceptors and are immobilised on the 
surface of the transducer. A solution (usually a buffer containing salts) containing the antigen 
is then exposed to the transducer where antibodies interact only with the antigens. To 
construct a biosensor, selectivity is a main consideration that should be taken into account 
while choosing bioreceptors.  
Reproducibility 
Reproducibility is the ability of the biosensor to generate identical responses for a duplicated 
experimental setup. The reproducibility is characterised by precision and accuracy of the 
transducer and electronics in a biosensor. Precision is the ability of the sensor to provide alike 
results every time a sample is measured and accuracy indicates the sensor’s capacity to 
provide a mean value close to the true value when a sample is measured more than once. 
Reproducible signals provide high reliability and robustness to the inference made on the 
response of a biosensor.  
Stability 
Stability is the degree of the susceptibility to ambient disturbances in and around the 
biosensing system. These disturbances can cause a drift in the output signals of a biosensor 
under measurement. This can cause an error in the measured concentration and can affect the 
precision and accuracy of the biosensor. Stability is the most crucial feature in applications 
where a biosensor requires long incubation steps or continuous monitoring. The response of 
transducers and electronics can be temperature sensitive, which may influence the stability of 
a biosensor. Therefore appropriate tuning of electronics is required to ensure a stable 
response of the sensor. Another factor that can influence the stability is the affinity of the 
bioreceptor. Affinity is the degree to which the analyte binds to the bioreceptor. Bioreceptors 
with high affinities encourage either strong electrostatic bonding or covalent linkage of the 
analyte that fortifies the stability of a biosensor. Another factor that affects the stability of a 
measurement is the degradation of the bioreceptor over a period of time.  
Sensitivity 
The minimum amount of analyte that can be detected by a biosensor defines its limit of 
detection (LOD) or sensitivity. In a number of medical and environmental monitoring 
applications, a biosensor is required to detect analyte concentration of as low as ng/ml or 
even fg/ml to confirm the present of traces of analytes in a sample. For instance, prostate 
specific antigen concentration of 4 ng/ml in blood is associated with prostate cancer for 
which doctors suggest biopsy tests. Hence sensitivity is considered as an important property 
of a biosensor. 
Linearity 
Linearity is the attribute that shows accuracy of the measured response (for a set of 
measurements with different concentrations of analyte) to a straight line, mathematically 
represented as y=mc, where c is the concentration of the analyte, y is the output signal and m 
is the sensitivity of the biosensor. Linearity of the biosensor can be associated with the 
resolution of biosensor and range of the analyte concentrations under test. The resolution of 
the biosensor is defined as the smallest change in the concentration of an analyte that is 
required to bring a change in the response of the biosensor. Depending on the application, a 
good resolution is required as most biosensor applications not only require analyte detection 
but also to measure concentrations of analyte within a wide working range. Another term 
associated with linearity is linear range that is defined as the range of analyte concentrations 
for which the biosensor response changes linearly with the concentration. 
 
Applications of biosensors 
Biosensors have a very wide range of applications that aim to improve the quality of life. 
This range covers their use for environmental monitoring, disease detection, food safety, 
defence, drug discovery and many more. One of the main applications of biosensors is the 
detection of biomolecules that are either indicators of a disease or targets of a drug. For 
example, electrochemical biosensing techniques can be used as clinical tools to detect protein 
cancer biomarkers [14-16]. Biosensors can also be used as platforms for monitoring food 
traceability, quality, safety, and nutritional value [17,18]. These applications fall in the 
category of "single shot" analysis tools, i.e. where cost effective and disposable sensing 
platforms are required for the application. On the other hand an application such as pollution 
monitoring [18,19] requires a biosensor to function from a few hours to several days. Such 
biosensors can be termed as "long term monitoring" analysis tools. Whether it is long term 
monitoring or single shot analysis, biosensors find their use as technological advanced 
devices both in resource limited settings and sophisticated medical setups: e.g. with 
applications in drug discovery [20-22]; for the detection of a number of chemical and 
biological agents that are considered as toxic materials of defence interest [23]; for use in 
artificial implantable devices such as pacemakers [24] and other prosthetic devices [25]; 
sewage epidemiology [26]. A range of electrochemical, optical and acoustic sensing 
techniques have been utilised, along with their integration into analytical devices for various 
applications. Figure 2 indicates different areas of research where biosensors have been used. 
 
 Figure 2 Major areas of applications for biosensors.  
 
Nanotechnology  
Irrespective of the field, miniaturization has always proved to be beneficial for varied 
reasons. For instance, reducing the size of the biosensor to the micro- or nanoscale can result 
in a better signal-to-noise ratio as well as in the possibility to use smaller volumes of sample, 
which means lower costs of the assay. Moreover, when going towards nanoscale dimensions, 
the surface-to-volume ratio of the sensing active area increases and the sizes of the detecting 
electrode and that of the target biomarker become comparable. This causes both reduced non-
specific binding and increased binding efficiency towards the target molecule. As a result, the 
bioreceptor becomes an active transducer for the sensing system and it becomes possible to 
perform single molecule detection [27].  
An interesting fact in an electrochemical system is that down to nanoscale dimensions the 
double layer capacitance dramatically decreases because of its dependence on the electrode 
area. As a result, the extremely low RsCdl time constant (where Rs is the solution resistance 
and Cdl is the double layer capacitance) allows ultra-fast electron-transfer kinetics and short-
life intermediate species can also be investigated. As the time constant decreases, the time 
required to accomplish a measurement also diminishes down to the nanosecond domain. 
Moreover, when Cdl decreases dramatically, a further interesting consequence is the 
possibility to perform measurements in media with a high solution resistance where normal 
macroelectrodes are not usable. In fact, by keeping constant the RsCdl factor, it is possible to 
perform measurements even without the need of a supporting electrolyte [28]. 
In terms of nanomaterials, the discovery of graphene and its oxidised form, graphene oxide, 
opened new frontiers in biosensors as well as in other research areas. Graphene is a pure form 
of carbon organized in single atom-thick sheets. This feature gives graphene exceptional 
chemical and physical properties.  
The integration of graphene, graphene oxide and carbon nanotubes (single or multiple one 
atom-thick carbon concentric tubes) as well as nanoparticles and nanowires of different 
materials are widely reported in the literature for electrode fabrication. Biosensors so 
fabricated can nowadays allow limits of detection lower than what was previously possible, 
enabling even single molecule detection. 
 
Impact of biosensors  
Looking at the never ending literature related to biosensors in the last few decades, it 
undoubtedly reveals that biosensors are attractive not only in academia but also in industry. 
Biosensor technology exploits the unique properties of a biological recognition event on a 
transducing device. In such an event, the interaction of the analyte with the bioreceptor is 
converted into a suitable output that is easily readable by the user. This approach not only 
exploits the molecular binding event, but also brings researchers from different areas of 
science and engineering to bridge their skills. Similar practices have created an immense 
impact on the early stage researchers in the field of biosensors. In addition it has opened new 
frontiers in the scientific research where large attention is being drawn towards development 
of technologies to benefit different areas including healthcare. Working in an 
interdisciplinary field helps to think out of the box and work together with distinct 
professionals where every idea contributes to make something substantial. A simple example 
is a pregnancy test biosensor where researchers from biology draw light on the biological 
aspects and cooperated with engineers to work on the electronics of the system for the 
readout. Finally, research from the laboratory is being transferred to customers worldwide 
because of management professionals. It would be naïve to think that biosensor research is 
confined to a niche - this can be seen clearly by the rapid increase of biosensors available in 
the market in recent times. Recently there has been a gradual increase in start-up companies 
based on biosensor technology worldwide, which is having a profound impact on the 
healthcare industrial sector. In general, it can be said that biosensors have found an important 
place in our society as they aim to improve the quality of life in diverse areas such as 
homeland, defence and security, agriculture, food safety, environment, medicine and 
pharmacology.   
 
Challenges in biosensing research  
Biosensors have been under development for around 50 years and the research in this field 
has made tremendous contributions in academia in the last 10 years. However, besides lateral 
flow pregnancy tests and electrochemical glucose biosensors, very few biosensors have 
achieved a global commercial success at the retail level. There are several factors for this: 
difficulties in translating academic research into commercially viable prototypes by industry; 
complex regulatory issues in clinical applications; and it has not always been trivial to either 
find researchers with a background in biosensor technology or engage researchers from 
different disciplines of science and engineering to work together. Another reason is that 
academic research is driven by propositions of peer review of science, funding agencies and 
politics that sometimes are characterized by various conflicts of interest. It is often a jury of 
academics who determine the priorities of funding agencies with legislators who seek 
considerable warrants for the funding they approve. If a subject can be made to appear fancy 
and attractive, it has a better chance for success. In this aspect biosensor technology has a 
certain distinction that has been proficiently sold as a priority. Biosensors should be aimed as 
practical devices to be used. Although biosensors employ fundamental sciences, it can hardly 
be rationalised as “curiosity driven” research. On the other hand the research in industry 
obeys the trend of "follow the money" to some extent. Given the success of commercial 
glucose sensors, biosensor research is of course very lucrative for the industry’s long term 
sustainability. However, it takes quite a long time to produce a commercially viable device 
from a proof of concept demonstrated in academia. This also involves a number of risks that 
industries are reluctant to face. 
As a result there are mandatory issues that are left unaddressed to produce a commercial 
biosensor. These are put into following points: 
 Identification of the market that is interested in biosensor of certain analyte of interest.  
 Clear cut advantages over existing methods for analyses of that analyte. 
 Testing the performance of the biosensor both in use and after storage. Response of a 
biosensor after six months storage is the absolute minimum for any practical 
commercial application. 
 Stability, costs and ease of manufacturing each component of the biosensor. 
 Hazards and ethics associated with the use of developed biosensor. 
The good news about biosensing technologies is that most of the barriers outlined above are 
being broken rapidly. High levels of investment have been poured into translational research 
worldwide, in particular for healthcare applications. This is bringing industry closer to 
academia in order to provide commercially viable products. On the other hand, there has been 
an outstanding improvement in the way scientists work across boundaries. Engineering and 
physical scientists have nowadays a much better understanding of basic biomolecular 
processes, while biochemists and molecular biologists have greater awareness of the 
capabilities of different technologies. The alliance of experts of different disciplines from the 
onset of biosensing development projects is a very attractive proposition that will certainly 
bring advanced and novel products to the market. 
 
Conclusions 
In vitro molecular biosensors are nowadays ubiquitous in biomedical diagnosis as well as a 
wide range of other areas such as point-of-care monitoring of treatment and disease 
progression, environmental monitoring, food control, drug discovery, forensics and 
biomedical research. Biosensor devices require the interaction of different disciplines and 
rely on very distinct aspects such as study of interactions of biorecognition elements with 
biomolecular analytes, immobilisation of biomolecules onto solid surfaces, development of 
anti-fouling surface chemistries, device design and fabrication, integration of biology with 
the devices, microfluidics, on-chip electronics, packaging, sampling techniques, etc. 
The rapid development in the field of biosensors in the past decades, both at the research and 
product development level, is due mainly to: i) developments in miniaturisation and 
microfabrication technologies; ii) the use of novel biorecognition molecules; iii) novel 
nanomaterials and nanostructured devices; iv) better interaction between life scientists and 
engineering/physical scientists. 
A range of target molecules and affinity reagents can be used for a wide range of biosensors. 
Antibody-based systems (Chapter 2) represent the gold standard in biosensors. Novel affinity 
reagents such as synthetic receptors are currently making way to replace antibodies on 
biosensors, in particular aptamers such as peptide aptamers (Chapter 3) and oligonucleotide 
aptamers (Chapter 4). DNA and oligonucleotide analogues such as PNA and LNA are often 
used as probe molecules for DNA and microRNA sensing (Chapter 4). Determination of 
protein glycosylation levels using lectins is currently of great interest in medical diagnosis 
(Chapter 5) as is the sensing of toxins in environmental monitoring (Chapter 6). Suitable 
bioconjugation strategies and stabilisation of biomolecules on electrodes is essential for the 
development of commercially viable biosensors (Chapter 7). 
A range of transduction techniques can be used in biosensing devices, including 
electrochemical sensors (Chapter 8), field-effect transistors (Chapter 9), optical sensors 
(Chapter 10) and acoustic-sensitive sensors (Chapter 11). Lateral flow systems (Chapter 12) 
have great promise for the development of inexpensive and easy to use point-of-care sensors 
beyond the traditional pregnancy tests, while lab-on-chip devices (Chapter 13) integrate 
different microfabrication techniques enabling biosensors to be employed in a wide range of 
applications using minute sample volumes and minimum sample preparation. 
 
Summary 
 Biosensors are nowadays ubiquitous in different areas of healthcare. 
 Pregnancy tests and glucose monitoring sensors are the two main examples of very 
successful biosensor devices. 
 A range of transduction techniques such as electrochemical, optical and acoustic, can 
be used for biosensors. 
 High affinity reagents such as antibodies, enzymes and synthetic biomolecules can be 
coupled with the transducer in order to provide specificity of the biosensors. 
 Nanotechnology is having a major impact in recent advances of biosensing 
technology. 
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